Tg Therapeutics (TGTX) Stock Price, Quote & News

Company Profile

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The com...

Industry: Biotechnology

Sector: Healthcare

Phone: 212 554 4484

Fax: 212 554 4531

Website: www.tgtherapeutics.com

Address:

3020 Carrington Mill Blvd., Suite 475, Morrisville, United States

Son_of_Shango May. 30 at 4:22 PM

$TGTX

0 · Reply

Stash_Cash May. 30 at 2:34 AM

$TGTX bought back my June $45 calls. 73% gain. I’ll try it again when we cross over $40 next

0 · Reply

MRTunity May. 29 at 9:24 PM

$TGTX once these moving averages get up around $35-$38 you will see that 💯 premium for $70-$75 BUYOUT 🤑 it’s coming Nobody wants it more than MW- people think he’s arrogant or cocky , called confidence and believing in your team and yourself! Pls sell and FO or short and get smoked! Been here for 3 yrs and ain’t going nowhere Don’t mind a boring cash cow that I believe will make me 50%+ yr over yr

2 · Reply

greko50 May. 29 at 9:07 PM

$TGTX I keep reiterating this co/stock is on total auto-pilot, and pay no attention to the daily moves up/down. Massive move higher after our last ER, definitely got ahead of ourselves in the mid 40's, so we're just consolidating that move for now. Definitely not the flashiest stock, but you'll be thankful in 6,9, 12 months from now if we're still around.....

3 · Reply

GreedyOgre May. 29 at 9:06 PM

$TGTX what is the price target on it?

2 · Reply

Sowa5000 May. 29 at 8:50 PM

$TGTX one of the best to own!

0 · Reply

MRTunity May. 29 at 8:37 PM

$TGTX when the entire retail board is pessimistic and bunch of Debbie downers - I get even more bullish lol 🐂 💪 Option chain certainly has all but decided NO BO- which makes potential upside premiums all that much sweeter. 🤤

0 · Reply

StockDreamin May. 29 at 8:08 PM

$TGTX guess i should start taking a short position here...seems like more guaranteed profits!

1 · Reply

Bobes May. 29 at 8:08 PM

$TGTX low vol sell off. Shes fine

1 · Reply

Wolves1 May. 29 at 8:07 PM

$TGTX 🤔

0 · Reply

TG Therapeutics to Participate in the Jefferies Global Healthcare Conference

2026-05-27T12:20:45.000Z - 3 days ago

TG Therapeutics reports ENHANCE trial meets primary endpoint

May 27, 2026, 7:30 AM EDT - 3 days ago

TG Therapeutics Announces Positive Topline Results from Phase 3 ENHANCE Trial

May 26, 2026, 7:30 AM EDT - 4 days ago

TG Therapeutics Announces Data Presentations for BRIUMVI® at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting

2026-05-07T07:02:48.000Z - 23 days ago

TG Therapeutics reports Q1 EPS 12c, consensus 28c

2026-05-07T03:05:19.000Z - 23 days ago

TG Therapeutics price target raised to $70 from $60 at H.C. Wainwright

May 6, 2026, 8:30 AM EDT - 24 days ago

TG Therapeutics Earnings Call Transcript: Q1 2026

May 6, 2026, 8:30 AM EDT - 24 days ago

TG Therapeutics Earnings release: Q1 2026

May 6, 2026, 8:30 AM EDT - 24 days ago

TG Therapeutics Quarterly report: Q1 2026

May 6, 2026, 7:00 AM EDT - 24 days ago

TG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance

Apr 30, 2026, 8:00 AM EDT - 4 weeks ago

TG Therapeutics Proxy statement: Proxy filing

Apr 30, 2026, 7:30 AM EDT - 4 weeks ago

TG Therapeutics to Host Conference Call on First Quarter 2026 Financial Results and Business Update

2026-04-15T11:48:15.000Z - 6 weeks ago

TG Therapeutics completes enrollment in Briumvi trial

Apr 15, 2026, 7:30 AM EDT - 6 weeks ago

TG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVI

2026-03-19T12:01:33.000Z - 2 months ago

TG Therapeutics secures additional $500M in non-dilutive capital

2026-03-19T12:01:19.000Z - 2 months ago

TG Therapeutics board expands share repurchase program to $300M

Mar 19, 2026, 7:30 AM EDT - 2 months ago

TG Therapeutics Secures an Additional $500 Million in Non-Dilutive Capital from Blue Owl and Expands Share Repurchase Program to $300 Million

2026-03-09T11:40:09.000Z - 2 months ago

TG Therapeutics announces publication of data from studies on Briumvi

Mar 9, 2026, 7:30 AM EDT - 2 months ago

Data Published in Neurology and Therapy Demonstrate Significant Reductions in Relapse and MRI Activity with BRIUMVI® in People with Highly Active Relapsing Multiple Sclerosis

Mar 6, 2026, 7:30 AM EST - 3 months ago

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting

2026-03-02T12:24:58.000Z - 3 months ago

Precision to get $7.5M in proceeds from TG Therapeutics for azer-cel milestone

DTIL

Mar 2, 2026, 7:01 AM EST - 3 months ago

Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis

DTIL

Feb 26, 2026, 8:30 AM EST - 3 months ago

TG Therapeutics Earnings Call Transcript: Q4 2025

Feb 26, 2026, 8:30 AM EST - 3 months ago

TG Therapeutics Annual report: Q4 2025

Feb 26, 2026, 8:30 AM EST - 3 months ago

TG Therapeutics Earnings release: Q4 2025

2026-02-26T12:15:51.000Z - 3 months ago

TG Therapeutics sees FY26 revenue $875M-$900M, consensus $897.64M

2026-02-26T12:08:07.000Z - 3 months ago

TG Therapeutics reports Q4 EPS 14c, consensus 33c

2026-02-26T12:06:42.000Z - 3 months ago

TG Therapeutics expects cash to fund business based on current operating plan

Feb 26, 2026, 7:00 AM EST - 3 months ago

TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Raises BRIUMVI Revenue Guidance

Feb 23, 2026, 7:30 AM EST - 3 months ago

TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2025 Financial Results and Business Update

2026-02-17T12:40:17.000Z - 3 months ago

TG Therapeutics announces long-term data on Briumvi published in JAMA Neurology

Feb 8, 2026, 4:17 PM EST - 3 months ago

TG Therapeutics Announces Collaboration with Christina Applegate to Raise Awareness of Multiple Sclerosis

Feb 6, 2026, 7:30 AM EST - 4 months ago

TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

2026-02-02T12:45:26.000Z - 4 months ago

TG Therapeutics price target lowered to $46 from $49 at JPMorgan

Jan 15, 2026, 10:31 AM EST - 4 months ago

These under-the-radar stocks combine fast growth with big upside potential

AGYS ASTH BBT CORT CTRE DCOM DOCN

2026-01-15T00:55:09.000Z - 4 months ago

TG Therapeutics price target raised to $39 from $37 at Goldman Sachs

2026-01-14T15:00:20.000Z - 4 months ago

TG Therapeutics rises 12.2%

Jan 13, 2026, 4:30 PM EST - 4 months ago

TG Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 4:30 PM EST - 4 months ago

TG Therapeutics Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 7, 2026, 7:30 AM EST - 5 months ago

TG Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Dec 2, 2025, 12:30 PM EST - 6 months ago

TG Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nov 28, 2025, 7:30 AM EST - 6 months ago

TG Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference

Nov 12, 2025, 10:00 AM EST - 7 months ago

TG Therapeutics Transcript: TD Cowen Immunology and Inflammation Summit

Nov 3, 2025, 8:30 AM EST - 7 months ago

TG Therapeutics Earnings Call Transcript: Q3 2025

Nov 3, 2025, 8:30 AM EST - 7 months ago

TG Therapeutics Quarterly report: Q3 2025

Nov 3, 2025, 8:30 AM EST - 7 months ago

TG Therapeutics Earnings release: Q3 2025

Oct 31, 2025, 7:30 AM EDT - 7 months ago

TG Therapeutics to Host Conference Call on Third Quarter 2025 Financial Results and Business Update

Oct 28, 2025, 7:30 AM EDT - 7 months ago

TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVI

Sep 24, 2025, 9:10 AM EDT - 8 months ago

New Data for BRIUMVI® Demonstrate 89.9% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 6 Years of Continuous BRIUMVI Treatment

Sep 10, 2025, 7:30 AM EDT - 9 months ago

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting

Sep 8, 2025, 10:30 AM EDT - 9 months ago

TG Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 7:30 AM EDT - 9 months ago

TG Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced Enrollment

Sep 4, 2025, 7:30 AM EDT - 9 months ago

TG Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 10:20 AM EDT - 9 months ago

TG Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Sep 3, 2025, 7:30 AM EDT - 9 months ago

TG Therapeutics Announces Completion of Existing Share Repurchase Program and Authorization of New $100 Million Program

Aug 28, 2025, 8:00 AM EDT - 9 months ago

TG Therapeutics to Participate in the Cantor Global Healthcare Conference

Aug 4, 2025, 8:30 AM EDT - 10 months ago

TG Therapeutics Earnings Call Transcript: Q2 2025

Aug 4, 2025, 8:30 AM EDT - 10 months ago

TG Therapeutics Quarterly report: Q2 2025

Aug 4, 2025, 8:30 AM EDT - 10 months ago

TG Therapeutics Earnings release: Q2 2025

Aug 4, 2025, 7:00 AM EDT - 10 months ago

TG Therapeutics Reports Second Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance

Jul 30, 2025, 7:30 AM EDT - 10 months ago

TG Therapeutics to Host Conference Call on Second Quarter 2025 Financial Results and Business Update

Jun 10, 2025, 10:40 AM EDT - 1 year ago

TG Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025

Jun 9, 2025, 4:51 PM EDT - 1 year ago

Evercore ISI's Julian Emanuel says now is the time to buy small-caps

CNS LEU RMBS SFM

Jun 6, 2025, 7:30 AM EDT - 1 year ago

TG Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Jun 4, 2025, 12:50 PM EDT - 1 year ago

TG Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

May 27, 2025, 7:30 AM EDT - 1 year ago

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting

May 5, 2025, 8:30 AM EDT - 1 year ago

TG Therapeutics Earnings Call Transcript: Q1 2025

May 5, 2025, 8:30 AM EDT - 1 year ago

TG Therapeutics Quarterly report: Q1 2025

May 5, 2025, 8:30 AM EDT - 1 year ago

TG Therapeutics Earnings release: Q1 2025

May 5, 2025, 7:00 AM EDT - 1 year ago

TG Therapeutics Reports First Quarter 2025 Financial Results and Raises BRIUMVI Full Year Revenue Guidance

Apr 30, 2025, 8:00 AM EDT - 1 year ago

TG Therapeutics Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

TG Therapeutics Proxy statement: Proxy Filing

Apr 30, 2025, 7:30 AM EDT - 1 year ago

TG Therapeutics to Host Conference Call on First Quarter 2025 Financial Results and Business Update

Apr 18, 2025, 8:00 AM EDT - 1 year ago

TG Therapeutics Proxy statement: Proxy Filing

Apr 10, 2025, 7:30 AM EDT - 1 year ago

TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting

Apr 7, 2025, 7:30 AM EDT - 1 year ago

TG Therapeutics Announces Two Publications Highlighting BRIUMVI in Medical Journals

Mar 7, 2025, 7:30 AM EST - 1 year ago

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting

Mar 4, 2025, 7:03 AM EST - 1 year ago

Privia Health, Corcept and three other low-key but high-earnings growth potential stocks to invest in 2025

CORT GILD PRVA TKO

Mar 3, 2025, 8:30 AM EST - 1 year ago

TG Therapeutics Earnings Call Transcript: Q4 2024

Mar 3, 2025, 8:30 AM EST - 1 year ago

TG Therapeutics Annual report: Q4 2024

Mar 3, 2025, 8:30 AM EST - 1 year ago

TG Therapeutics Earnings release: Q4 2024

Feb 27, 2025, 7:30 AM EST - 1 year ago

TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

Feb 26, 2025, 7:30 AM EST - 1 year ago

TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2024 Financial Results and Business Update

Feb 18, 2025, 10:20 AM EST - 1 year ago

20 stocks of companies expected to put up numbers to back investors' new ‘growth mindset'

ARWR AUB CRK CYTK EXE KRYS MARA

Jan 13, 2025, 7:30 PM EST - 1 year ago

TG Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 13, 2025, 7:30 PM EST - 1 year ago

TG Therapeutics Slides: FY 2025

Jan 9, 2025, 7:30 AM EST - 1 year ago

TG Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Dec 4, 2024, 7:36 AM EST - 1 year ago

20 stocks likely to lag the S&P 500 over the next year — for this one reason

CELH CENX CNXC CRSR CXM FLG GEO

Dec 3, 2024, 10:00 AM EST - 1 year ago

TG Therapeutics Transcript: 7th Annual Evercore ISI HealthCONx Healthcare Conference

Nov 29, 2024, 8:00 AM EST - 1 year ago

TG Therapeutics to Participate in the Evercore HealthCONx Conference

Nov 21, 2024, 6:00 AM EST - 1 year ago

TG Therapeutics Ranked Number One Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™

Nov 4, 2024, 9:00 AM EST - 1 year ago

FUJIFILM Diosynth Biotechnologies Signs Manufacturing Supply Agreement with TG Therapeutics

Nov 4, 2024, 8:30 AM EST - 1 year ago

TG Therapeutics Earnings Call Transcript: Q3 2024

Nov 4, 2024, 8:30 AM EST - 1 year ago

TG Therapeutics Quarterly report: Q3 2024

Nov 4, 2024, 8:30 AM EST - 1 year ago

TG Therapeutics Earnings release: Q3 2024

Nov 1, 2024, 8:06 AM EDT - 1 year ago

TG Therapeutics to Host Conference Call on Third Quarter 2024 Financial Results and Business Update

Sep 18, 2024, 7:15 AM EDT - 1 year ago

New BRIUMVI® (ublituximab-xiiy) Data from the ENHANCE Phase 3b Study Show Rapid 30-Minute Infusions are Well Tolerated in Patients with Relapsing Forms of Multiple Sclerosis

Sep 18, 2024, 7:00 AM EDT - 1 year ago

New Data for BRIUMVI® (ublituximab-xiiy) Demonstrate that 92% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 5 Years of Treatment

Sep 5, 2024, 7:30 AM EDT - 1 year ago

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI at the 2024 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting

Aug 6, 2024, 9:01 AM EDT - 1 year ago

HealthCare Royalty and Blue Owl Announce $250M Debt Financing with TG Therapeutics

Aug 6, 2024, 8:30 AM EDT - 1 year ago

TG Therapeutics Earnings Call Transcript: Q2 2024

Aug 6, 2024, 8:30 AM EDT - 1 year ago

TG Therapeutics Quarterly report: Q2 2024

Aug 6, 2024, 8:30 AM EDT - 1 year ago

TG Therapeutics Earnings release: Q2 2024

Aug 5, 2024, 7:30 AM EDT - 1 year ago

TG Therapeutics to Host Conference Call on Second Quarter 2024 Financial Results and Business Update

Son_of_Shango May. 30 at 4:22 PM

$TGTX

0 · Reply

Stash_Cash May. 30 at 2:34 AM

$TGTX bought back my June $45 calls. 73% gain. I’ll try it again when we cross over $40 next

0 · Reply

MRTunity May. 29 at 9:24 PM

2 · Reply

greko50 May. 29 at 9:07 PM

3 · Reply

GreedyOgre May. 29 at 9:06 PM

$TGTX what is the price target on it?

2 · Reply

Sowa5000 May. 29 at 8:50 PM

$TGTX one of the best to own!

0 · Reply

MRTunity May. 29 at 8:37 PM

0 · Reply

StockDreamin May. 29 at 8:08 PM

$TGTX guess i should start taking a short position here...seems like more guaranteed profits!

1 · Reply

Bobes May. 29 at 8:08 PM

$TGTX low vol sell off. Shes fine

1 · Reply

Wolves1 May. 29 at 8:07 PM

$TGTX 🤔

0 · Reply

Insidersknow May. 29 at 7:58 PM

$TGTX disgusting

0 · Reply

stocky1234 May. 29 at 7:53 PM

$TGTX wank as usual

0 · Reply

MRTunity May. 29 at 7:52 PM

$TGTX I’m ready for a $75 🎯 BO LFG… screen shot my YOLO trading account for shits n giggles MW don’t let me down- take best price you can get below Aug21 pls 🙏 🤑

2 · Reply

Biocreeper May. 29 at 7:38 PM

$TGTX well schucks, with the enhance data coming out earlier this week, I would have guessed a better week.

3 · Reply

Son_of_Shango May. 29 at 7:38 PM

$TGTX

0 · Reply

Luckybreak May. 29 at 7:27 PM

$TGTX What is happening to daily volume this Friday

0 · Reply

CedarPark May. 29 at 7:18 PM

$TGTX very low volume today, drifted lower and oversold right now. Going to add a small amount more, I think next week we move back up.

0 · Reply

TheMach99 May. 29 at 6:19 PM

$TGTX

0 · Reply

BillionaireMotion May. 29 at 6:01 PM

$TGTX lets trend

0 · Reply

Rmona423 May. 29 at 5:14 PM

$TGTX I would love to know if MW had any offers floated to him in the last 6-10 months. I don’t know why a BP wouldn’t be knocking down his door. I understand expectation vs. reality will be a comment I hear back on this post. But I would hope a mentor or peer would be telling MW strike while the iron is getting hot.

2 · Reply

Insidersknow May. 29 at 5:10 PM

$TGTX this is exactly why it would make sense for some people. It is dead money. Going nowhere or staying sideways. People want to use their money and take advantage of better opportunities in the market.

1 · Reply

Believe2 May. 29 at 5:04 PM

$TGTX I have been in and out of this for years …out right now …made $ here …the hope was always a BO …not going to happen with this CEO he is really terrible IMO and holds the great product back …..will probably jump in if it goes lower but so much else out there with upside not side ways like this

1 · Reply

Market Cap	5.94B
Revenue (ttm)	616.29M
Net Income (ttm)	447.18M
EPS (ttm)	N/A
PE Ratio	13.47
Forward PE	29.98
Profit Margin	72.56%
Debt to Equity Ratio	1.28

Volume	1,224,800
Avg Vol	2,036,042
Day's Range	N/A - N/A
Shares Out	153.08M
Stochastic %K	4%
Beta	1.68
Analysts	Sell
Price Target	$48.00